Tenaya Therapeutics, Inc. Board of Directors

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Mr. Faraz Ali M.B.A.

Mr. Faraz Ali M.B.A.

CEO, Interim Principal Financial Officer & Director

Dr. Eric N. Olson Ph.D.

Dr. Eric N. Olson Ph.D.

Scientific Founder & Member of Scientific Advisory Board

Dr. Deepak Srivastava M.D.

Dr. Deepak Srivastava M.D.

Scientific Founder, Chairman of Scientific Advisory Board & Director

Ms. Michelle Corral

Ms. Michelle Corral

Vice President of Investor Relationship & Corporate Communications

Dr. Kee-Hong Kim Ph.D.

Dr. Kee-Hong Kim Ph.D.

Chief Technology Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.